Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
51. |
ECCT/14/02/03 | A Phase 1/2 Randomized, Double-Blind, Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus pneumoniae Whole Cell Vaccine Formulated with Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers (12-15 Months of Age) |
Principal Investigator(s) 1. Nekoye Namungu Otsyula 2. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute (KEMRI)/Walter Reed Project, Kombewa Clinical Research Center |
View |
52. |
ECCT/13/07/05 | Single Dose Escalating, Single-blind Phase 1 Trial in Healthy Male Volunteers to Evalute the Safety, Tolerability and the Pharmacokinetics of Oleylphosphocholine. |
Principal Investigator(s) 1. Rashid Ravasco Juma Site(s) in Kenya KEMRI Centre for Clinical Research |
View |
53. |
ECCT/10/09/05 | A5225/ HiFLAC A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis A Multicenter Trial of the AIDS Clinical Trials Group (ACTG) |
Principal Investigator(s) 1. Deborah Chepngeno langat Site(s) in Kenya 1. |
View |
54. |
ECCT/10/03/03 | High-Dose Fluconazole Treatment in AIDS-Associated CM A5225/HiFLAC: A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
View |
55. |
ECCT/11/12/04 | PENNVAX-G DNA/MVA HIV Vaccine Phase 1 trial A Phase I Study of the Safety and Immunogenicity of PENNVAX™-G DNA (Env & Gag) Administered by Intramuscular Biojector® 2000 or by CELLECTRA® Intramuscular Electroporation Device Followed by MVACMDR (HIV-1 CM235 env/ CM240 gag/pol) Boost in Healthy, HIV Uninfected Adults |
Principal Investigator(s) 1. FREDRICK KIPYEGO SAWE Site(s) in Kenya KEMRI/Walter Reed Project-Kericho |
View |